Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Viking+Therapeutics+%28VKTX%29+Announces+Positive+Top-Line+Results+from+Phase+2+VENTURE+Trial+of+Dual+GLP-1GIP+Receptor+Agonist+VK2735+in+Patients+with+Obesity/22837321.html for the full story.